Researchers developed a model using routine clinical data to identify optimal glucose-lowering therapies for patients with type 2 diabetes (T2D). Individuals receiving model-predicted optimal therapy ...

A class of diabetes drugs known as SGLT2 inhibitors may significantly reduce the risk of organ rejection in patients ...

A major new study reveals that older adults with cancer and type 2 diabetes who take GLP-1 receptor agonist medications (GLP-1RAs) experience significantly better overall survival rates compared to ...

Some health-obsessed Americans believe the next antiaging therapeutic already exists—in the medicine cabinets of millions of diabetes patients. The widely used class of drugs, called SGLT2 inhibitors ...

Antidiabetic drug classes show varied associations with liver outcomes in T2DM, with SGLT2 inhibitors and GLP-1 RA ranking highest.

GLP-1 drugs like Ozempic and Wegovy offer surprising benefits beyond weight loss, but also carry unexpected risks.

Consistent adherence to sodium-glucose cotransporter 2 (SGLT2) inhibitors in individuals with type 2 diabetes reduces the risk of hospitalization, supporting targeted interventions to improve ...

When diabetes causes CKD, it’s sometimes called diabetic kidney disease. Elevated blood sugar levels that result from diabetes can damage the tiny blood vessels inside your kidneys. As a result, your ...

A large international study suggests that a subset of people with Type 2 diabetes carry genetic variants that blunt the effectiveness of widely used GLP-1–based drugs, despite unexpectedly elevated ...